Gilead Science Korea's HIV treatment drug Biktarvy will be reduced by signing PVA negotiations. The price will be adjusted from 24,631 won to 23,900 won and the new drug price is expected to take effect from April 1. According to the industry on the 21st, the MOHW is pushing for a "revision of the drug benefit list and upper limit table" with such contents. The PVA adjustment item, Biktarvy, is a new drug registered as a drug negotiation, up more than 30% from the expected amount of drug negotiations, making it the subject of negotiations.

The company and the NHIS will negotiate drug prices to agree on a reduction rate within up to 10% below the current upper limit. Biktarvy is leading the HIV treatment